These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 9254325)
1. [From an idea to a completed drug: a process of 10-15 years]. Hacksell U; Johnsson G Lakartidningen; 1997 Jul; 94(28-29):2561-6. PubMed ID: 9254325 [No Abstract] [Full Text] [Related]
2. Cutting the cost of drug development? Rawlins MD Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531 [No Abstract] [Full Text] [Related]
4. [From the chemical product to the authorization of drug marketing]. Caulin C Rev Prat; 2002 Mar; 52(5):486-90. PubMed ID: 11949499 [TBL] [Abstract][Full Text] [Related]
5. Medicine. A portfolio model of drug development for tuberculosis. Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969 [No Abstract] [Full Text] [Related]
6. Clinical trials in India: balancing economic opportunity with the public health context. Dandona L Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189 [No Abstract] [Full Text] [Related]
8. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
9. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
10. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
12. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431 [No Abstract] [Full Text] [Related]
13. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency. Schultheis LW; Rappaport BA Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189 [No Abstract] [Full Text] [Related]
14. Drug evaluation and approval process in the European Union. San Miguel MT; Vargas E Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405 [No Abstract] [Full Text] [Related]
16. Biotech blockbusters consolidate markets. Lawrence S Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033 [No Abstract] [Full Text] [Related]
17. From exotic spice to modern drug? Singh S Cell; 2007 Sep; 130(5):765-8. PubMed ID: 17803897 [TBL] [Abstract][Full Text] [Related]
18. Drug development process for a product with a primary pediatric indication. Allen AJ; Michelson D J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061 [TBL] [Abstract][Full Text] [Related]
20. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]. Ainsworth MA Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]